𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

✍ Scribed by Naomi P. Visanji; Rob M.A. de Bie; Tom H. Johnston; Andrew C. McCreary; Jonathan M. Brotchie; Susan H. Fox

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
540 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society

📜 SIMILAR VOLUMES

Stimulation of cannabinoid receptors red
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

Fipamezole (JP-1730) is a potent α2 adre
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti

Histamine H3 receptor agonists reduce L-
Histamine H3 receptor agonists reduce L-dopa–induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Jordi Gomez-Ramirez; Tom H. Johnston; Naomi P. Visanji; Susan H. Fox; Jonathan M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract L‐dopa–induced dyskinesia (LID) remains a major complication of the treatment of Parkinson's disease. The neural mechanisms underlying LID are thought to involve overactivity of striatal glutamatergic neurotransmission, with resultant underactivation of the output regions of the basal g

The selective mu-opioid receptor antagon
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the